Answers are grounded in this paper and cite their sources.
Background Management of severe anticoagulant rodenticide poisoning relies mainly on vitamin K 1 (VK 1 ) therapy, which often requires prolonged administration when long-acting anticoagulant rodenticides (LAARs) are involved. Key Clinical Question Can a direct oral anticoagulant (DOAC) be safely reintroduced in a patient at high risk of thrombosis recurrence whose LAAR poisoning is being managed with prolonged VK 1 therapy? Clinical Approach We report the case of a patient receiving rivaroxaban for recurrent thrombosis who ingested massive amounts of brodifacoum, difenacoum, and difethialone over the course of one month. He developed severe vitamin K–dependent coagulopathy (INR>26) with hematuria, necessitating discontinuation of rivaroxaban and initiation of intravenous, followed by long-term oral, VK 1 therapy. Rivaroxaban was successfully reintroduced under close clinical and laboratory monitoring after several days of ongoing oral VK 1 therapy. Conclusions This case demonstrates the feasibility of resuming DOAC therapy during VK 1 treatment after LAARs poisoning.
No takes yet. Share an insight, caveat, or question.
Escal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: